No edit summary
No edit summary
Line 20: Line 20:
|
|
|
|
|-|[[BRST5:Columnar_cell_lesions,_including_flat_epithelial_atypia_|Columnar cell lesions, including flat epithelial atypia ]]
|-
|[[BRST5:Columnar_cell_lesions,_including_flat_epithelial_atypia_|Columnar cell lesions, including flat epithelial atypia ]]
|Disease
|Disease
|
|
Line 30: Line 31:
|
|
|
|
|-|[[BRST5:Atypical_ductal_hyperplasia|Atypical ductal hyperplasia]]
|-
|[[BRST5:Atypical_ductal_hyperplasia|Atypical ductal hyperplasia]]
|Disease
|Disease
|
|
Line 40: Line 42:
|
|
|
|
|-|[[BRST5:Sclerosing_adenosis|Sclerosing adenosis]]
|-
|[[BRST5:Sclerosing_adenosis|Sclerosing adenosis]]
|Disease
|Disease
|
|
Line 50: Line 53:
|
|
|
|
|-|[[BRST5:Apocrine_adenosis_and_adenoma|Apocrine adenosis and adenoma]]
|-
|[[BRST5:Apocrine_adenosis_and_adenoma|Apocrine adenosis and adenoma]]
|Disease
|Disease
|
|
Line 60: Line 64:
|
|
|
|
|-|[[BRST5:Microglandular_adenosis_|Microglandular adenosis ]]
|-
|[[BRST5:Microglandular_adenosis_|Microglandular adenosis ]]
|Disease
|Disease
|
|
Line 70: Line 75:
|
|
|
|
|-|[[BRST5:Radial_scar_/_complex_sclerosing_lesion_|Radial scar / complex sclerosing lesion ]]
|-
|[[BRST5:Radial_scar_/_complex_sclerosing_lesion_|Radial scar / complex sclerosing lesion ]]
|Disease
|Disease
|
|
Line 80: Line 86:
|
|
|
|
|-|[[BRST5:Tubular_adenoma_|Tubular adenoma ]]
|-
|[[BRST5:Tubular_adenoma_|Tubular adenoma ]]
|Disease
|Disease
|
|
Line 90: Line 97:
|
|
|
|
|-|[[BRST5:Lactating_adenoma_|Lactating adenoma ]]
|-
|[[BRST5:Lactating_adenoma_|Lactating adenoma ]]
|Disease
|Disease
|
|
Line 100: Line 108:
|
|
|
|
|-|[[BRST5:Ductal_adenoma|Ductal adenoma]]
|-
|[[BRST5:Ductal_adenoma|Ductal adenoma]]
|Disease
|Disease
|
|
Line 110: Line 119:
|
|
|
|
|-|[[BRST5:Pleomorphic_adenoma|Pleomorphic adenoma]]
|-
|[[BRST5:Pleomorphic_adenoma|Pleomorphic adenoma]]
|Disease
|Disease
|
|
Line 120: Line 130:
|
|
|
|
|-|[[BRST5:Adenomyoepithelioma|Adenomyoepithelioma]]
|-
|[[BRST5:Adenomyoepithelioma|Adenomyoepithelioma]]
|Disease
|Disease
|
|
Line 130: Line 141:
|
|
|
|
|-|[[BRST5:Malignant_adenomyoepithelioma|Malignant adenomyoepithelioma]]
|-
|[[BRST5:Malignant_adenomyoepithelioma|Malignant adenomyoepithelioma]]
|Disease
|Disease
|
|
Line 140: Line 152:
|
|
|
|
|-|[[BRST5:Intraductal_papilloma|Intraductal papilloma]]
|-
|[[BRST5:Intraductal_papilloma|Intraductal papilloma]]
|Disease
|Disease
|
|
Line 150: Line 163:
|
|
|
|
|-|[[BRST5:Papillary_ductal_carcinoma_in_situ|Papillary ductal carcinoma in situ]]
|-
|[[BRST5:Papillary_ductal_carcinoma_in_situ|Papillary ductal carcinoma in situ]]
|Disease
|Disease
|
|
Line 160: Line 174:
|
|
|
|
|-|[[BRST5:Encapsulated_papillary_carcinoma|Encapsulated papillary carcinoma]]
|-
|[[BRST5:Encapsulated_papillary_carcinoma|Encapsulated papillary carcinoma]]
|Disease
|Disease
|
|
Line 170: Line 185:
|
|
|
|
|-|[[BRST5:Solid_papillary_carcinoma_(in_situ_and_invasive)|Solid papillary carcinoma (in situ and invasive)]]
|-
|[[BRST5:Solid_papillary_carcinoma_(in_situ_and_invasive)|Solid papillary carcinoma (in situ and invasive)]]
|Disease
|Disease
|
|
Line 180: Line 196:
|
|
|
|
|-|[[BRST5:Invasive_papillary_carcinoma|Invasive papillary carcinoma]]
|-
|[[BRST5:Invasive_papillary_carcinoma|Invasive papillary carcinoma]]
|Disease
|Disease
|
|
Line 190: Line 207:
|
|
|
|
|-|[[BRST5:Atypical_lobular_hyperplasia_|Atypical lobular hyperplasia ]]
|-
|[[BRST5:Atypical_lobular_hyperplasia_|Atypical lobular hyperplasia ]]
|Disease
|Disease
|
|
Line 200: Line 218:
|
|
|
|
|-|[[BRST5:Lobular_carcinoma_in_situ|Lobular carcinoma in situ]]
|-
|[[BRST5:Lobular_carcinoma_in_situ|Lobular carcinoma in situ]]
|Disease
|Disease
|
|
Line 210: Line 229:
|
|
|
|
|-|[[BRST5:Ductal_carcinoma_in_situ_|Ductal carcinoma in situ ]]
|-
|[[BRST5:Ductal_carcinoma_in_situ_|Ductal carcinoma in situ ]]
|Disease
|Disease
|
|
Line 220: Line 240:
|
|
|
|
|-|[[BRST5:Invasive_breast_carcinoma:_General_overview|Invasive breast carcinoma: General overview]]
|-
|[[BRST5:Invasive_breast_carcinoma:_General_overview|Invasive breast carcinoma: General overview]]
|Disease
|Disease
|
|
Line 230: Line 251:
|
|
|
|
|-|[[BRST5:Invasive_breast_carcinoma_of_no_special_type|Invasive breast carcinoma of no special type]]
|-
|[[BRST5:Invasive_breast_carcinoma_of_no_special_type|Invasive breast carcinoma of no special type]]
|Disease
|Disease
|
|
Line 240: Line 262:
|
|
|
|
|-|[[BRST5:Microinvasive_carcinoma|Microinvasive carcinoma]]
|-
|[[BRST5:Microinvasive_carcinoma|Microinvasive carcinoma]]
|Disease
|Disease
|
|
Line 250: Line 273:
|
|
|
|
|-|[[BRST5:Invasive_lobular_carcinoma_|Invasive lobular carcinoma ]]
|-
|[[BRST5:Invasive_lobular_carcinoma_|Invasive lobular carcinoma ]]
|Disease
|Disease
|
|
Line 260: Line 284:
|
|
|
|
|-|[[BRST5:Tubular_carcinoma|Tubular carcinoma]]
|-
|[[BRST5:Tubular_carcinoma|Tubular carcinoma]]
|Disease
|Disease
|
|
Line 270: Line 295:
|
|
|
|
|-|[[BRST5:Cribriform_carcinoma|Cribriform carcinoma]]
|-
|[[BRST5:Cribriform_carcinoma|Cribriform carcinoma]]
|Disease
|Disease
|
|
Line 280: Line 306:
|
|
|
|
|-|[[BRST5:Mucinous_carcinoma|Mucinous carcinoma]]
|-
|[[BRST5:Mucinous_carcinoma|Mucinous carcinoma]]
|Disease
|Disease
|
|
Line 290: Line 317:
|
|
|
|
|-|[[BRST5:Mucinous_cystadenocarcinoma|Mucinous cystadenocarcinoma]]
|-
|[[BRST5:Mucinous_cystadenocarcinoma|Mucinous cystadenocarcinoma]]
|Disease
|Disease
|
|
Line 300: Line 328:
|
|
|
|
|-|[[BRST5:Invasive_micropapillary_carcinoma|Invasive micropapillary carcinoma]]
|-
|[[BRST5:Invasive_micropapillary_carcinoma|Invasive micropapillary carcinoma]]
|Disease
|Disease
|
|
Line 310: Line 339:
|
|
|
|
|-|[[BRST5:Carcinoma_with_apocrine_differentiation|Carcinoma with apocrine differentiation]]
|-
|[[BRST5:Carcinoma_with_apocrine_differentiation|Carcinoma with apocrine differentiation]]
|Disease
|Disease
|
|
Line 320: Line 350:
|
|
|
|
|-|[[BRST5:Metaplastic_carcinoma|Metaplastic carcinoma]]
|-
|[[BRST5:Metaplastic_carcinoma|Metaplastic carcinoma]]
|Disease
|Disease
|
|
Line 330: Line 361:
|
|
|
|
|-|[[BRST5:Acinic_cell_carcinoma|Acinic cell carcinoma]]
|-
|[[BRST5:Acinic_cell_carcinoma|Acinic cell carcinoma]]
|Disease
|Disease
|
|
Line 340: Line 372:
|
|
|
|
|-|[[BRST5:Adenoid_cystic_carcinoma|Adenoid cystic carcinoma]]
|-
|[[BRST5:Adenoid_cystic_carcinoma|Adenoid cystic carcinoma]]
|Disease
|Disease
|
|
Line 350: Line 383:
|
|
|
|
|-|[[BRST5:Secretory_carcinoma_|Secretory carcinoma ]]
|-
|[[BRST5:Secretory_carcinoma_|Secretory carcinoma ]]
|Disease
|Disease
|
|
Line 360: Line 394:
|
|
|
|
|-|[[BRST5:Mucoepidermoid_carcinoma|Mucoepidermoid carcinoma]]
|-
|[[BRST5:Mucoepidermoid_carcinoma|Mucoepidermoid carcinoma]]
|Disease
|Disease
|
|
Line 370: Line 405:
|
|
|
|
|-|[[BRST5:Polymorphous_adenocarcinoma|Polymorphous adenocarcinoma]]
|-
|[[BRST5:Polymorphous_adenocarcinoma|Polymorphous adenocarcinoma]]
|Disease
|Disease
|
|
Line 380: Line 416:
|
|
|
|
|-|[[BRST5:Tall_cell_carcinoma_with_reversed_polarity|Tall cell carcinoma with reversed polarity]]
|-
|[[BRST5:Tall_cell_carcinoma_with_reversed_polarity|Tall cell carcinoma with reversed polarity]]
|Disease
|Disease
|
|
Line 390: Line 427:
|
|
|
|
|-|[[BRST5:Neuroendocrine_tumour|Neuroendocrine tumour]]
|-
|[[BRST5:Neuroendocrine_tumour|Neuroendocrine tumour]]
|Disease
|Disease
|
|
Line 400: Line 438:
|
|
|
|
|-|[[BRST5:Neuroendocrine_carcinoma|Neuroendocrine carcinoma]]
|-
|[[BRST5:Neuroendocrine_carcinoma|Neuroendocrine carcinoma]]
|Disease
|Disease
|
|
Line 410: Line 449:
|
|
|
|
|-|[[BRST5:Hamartoma_|Hamartoma ]]
|-
|[[BRST5:Hamartoma_|Hamartoma ]]
|Disease
|Disease
|
|
Line 420: Line 460:
|
|
|
|
|-|[[BRST5:Fibroadenoma_|Fibroadenoma ]]
|-
|[[BRST5:Fibroadenoma_|Fibroadenoma ]]
|Disease
|Disease
|
|
Line 430: Line 471:
|
|
|
|
|-|[[BRST5:Phyllodes_tumour_|Phyllodes tumour ]]
|-
|[[BRST5:Phyllodes_tumour_|Phyllodes tumour ]]
|Disease
|Disease
|
|
Line 440: Line 482:
|
|
|
|
|-|[[BRST5:Syringomatous_tumour_|Syringomatous tumour ]]
|-
|[[BRST5:Syringomatous_tumour_|Syringomatous tumour ]]
|Disease
|Disease
|
|
Line 450: Line 493:
|
|
|
|
|-|[[BRST5:Nipple_adenoma_|Nipple adenoma ]]
|-
|[[BRST5:Nipple_adenoma_|Nipple adenoma ]]
|Disease
|Disease
|
|
Line 460: Line 504:
|
|
|
|
|-|[[BRST5:Paget_disease_of_the_breast|Paget disease of the breast]]
|-
|[[BRST5:Paget_disease_of_the_breast|Paget disease of the breast]]
|Disease
|Disease
|
|
Line 470: Line 515:
|
|
|
|
|-|[[BRST5:Haemangioma|Haemangioma]]
|-
|[[BRST5:Haemangioma|Haemangioma]]
|Disease
|Disease
|
|
Line 480: Line 526:
|
|
|
|
|-|[[BRST5:Angiomatosis|Angiomatosis]]
|-
|[[BRST5:Angiomatosis|Angiomatosis]]
|Disease
|Disease
|
|
Line 490: Line 537:
|
|
|
|
|-|[[BRST5:Atypical_vascular_lesions_|Atypical vascular lesions ]]
|-
|[[BRST5:Atypical_vascular_lesions_|Atypical vascular lesions ]]
|Disease
|Disease
|
|
Line 500: Line 548:
|
|
|
|
|-|[[BRST5:Postradiation_angiosarcoma_of_the_breast|Postradiation angiosarcoma of the breast]]
|-
|[[BRST5:Postradiation_angiosarcoma_of_the_breast|Postradiation angiosarcoma of the breast]]
|Disease
|Disease
|
|
Line 510: Line 559:
|
|
|
|
|-|[[BRST5:Primary_angiosarcoma_of_the_breast|Primary angiosarcoma of the breast]]
|-
|[[BRST5:Primary_angiosarcoma_of_the_breast|Primary angiosarcoma of the breast]]
|Disease
|Disease
|
|
Line 520: Line 570:
|
|
|
|
|-|[[BRST5:Nodular_fasciitis|Nodular fasciitis]]
|-
|[[BRST5:Nodular_fasciitis|Nodular fasciitis]]
|Disease
|Disease
|
|
Line 530: Line 581:
|
|
|
|
|-|[[BRST5:Myofibroblastoma|Myofibroblastoma]]
|-
|[[BRST5:Myofibroblastoma|Myofibroblastoma]]
|Disease
|Disease
|
|
Line 540: Line 592:
|
|
|
|
|-|[[BRST5:Desmoid_fibromatosis_|Desmoid fibromatosis ]]
|-
|[[BRST5:Desmoid_fibromatosis_|Desmoid fibromatosis ]]
|Disease
|Disease
|
|
Line 550: Line 603:
|
|
|
|
|-|[[BRST5:Inflammatory_myofibroblastic_tumour_|Inflammatory myofibroblastic tumour ]]
|-
|[[BRST5:Inflammatory_myofibroblastic_tumour_|Inflammatory myofibroblastic tumour ]]
|Disease
|Disease
|
|
Line 560: Line 614:
|
|
|
|
|-|[[BRST5:Schwannoma_|Schwannoma ]]
|-
|[[BRST5:Schwannoma_|Schwannoma ]]
|Disease
|Disease
|
|
Line 570: Line 625:
|
|
|
|
|-|[[BRST5:Neurofibroma_|Neurofibroma ]]
|-
|[[BRST5:Neurofibroma_|Neurofibroma ]]
|Disease
|Disease
|
|
Line 580: Line 636:
|
|
|
|
|-|[[BRST5:Granular_cell_tumour|Granular cell tumour]]
|-
|[[BRST5:Granular_cell_tumour|Granular cell tumour]]
|Disease
|Disease
|
|
Line 590: Line 647:
|
|
|
|
|-|[[BRST5:Leiomyoma|Leiomyoma]]
|-
|[[BRST5:Leiomyoma|Leiomyoma]]
|Disease
|Disease
|
|
Line 600: Line 658:
|
|
|
|
|-|[[BRST5:Leiomyosarcoma_|Leiomyosarcoma ]]
|-
|[[BRST5:Leiomyosarcoma_|Leiomyosarcoma ]]
|Disease
|Disease
|
|
Line 610: Line 669:
|
|
|
|
|-|[[BRST5:Lipoma_|Lipoma ]]
|-
|[[BRST5:Lipoma_|Lipoma ]]
|Disease
|Disease
|
|
Line 620: Line 680:
|
|
|
|
|-|[[BRST5:Angiolipoma_|Angiolipoma ]]
|-
|[[BRST5:Angiolipoma_|Angiolipoma ]]
|Disease
|Disease
|
|
Line 630: Line 691:
|
|
|
|
|-|[[BRST5:Liposarcoma_|Liposarcoma ]]
|-
|[[BRST5:Liposarcoma_|Liposarcoma ]]
|Disease
|Disease
|
|
Line 640: Line 702:
|
|
|
|
|-|[[BRST5:Pseudoangiomatous_stromal_hyperplasia|Pseudoangiomatous stromal hyperplasia]]
|-
|[[BRST5:Pseudoangiomatous_stromal_hyperplasia|Pseudoangiomatous stromal hyperplasia]]
|Disease
|Disease
|
|
Line 650: Line 713:
|
|
|
|
|-|[[BRST5:Extranodal_marginal_zone_lymphoma_of_mucosa-associated_lymphoid_tissue_(MALT_lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]
|-
|[[BRST5:Extranodal_marginal_zone_lymphoma_of_mucosa-associated_lymphoid_tissue_(MALT_lymphoma)|Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)]]
|Disease
|Disease
|
|
Line 660: Line 724:
|
|
|
|
|-|[[BRST5:Follicular_lymphoma_|Follicular lymphoma ]]
|-
|[[BRST5:Follicular_lymphoma_|Follicular lymphoma ]]
|Disease
|Disease
|
|
Line 670: Line 735:
|
|
|
|
|-|[[BRST5:Diffuse_large_B-cell_lymphoma_|Diffuse large B-cell lymphoma ]]
|-
|[[BRST5:Diffuse_large_B-cell_lymphoma_|Diffuse large B-cell lymphoma ]]
|Disease
|Disease
|
|
Line 680: Line 746:
|
|
|
|
|-|[[BRST5:Burkitt_lymphoma|Burkitt lymphoma]]
|-
|[[BRST5:Burkitt_lymphoma|Burkitt lymphoma]]
|Disease
|Disease
|
|
Line 690: Line 757:
|
|
|
|
|-|[[BRST5:Breast_implant-associated_anaplastic_large_cell_lymphoma_|Breast implant-associated anaplastic large cell lymphoma ]]
|-
|[[BRST5:Breast_implant-associated_anaplastic_large_cell_lymphoma_|Breast implant-associated anaplastic large cell lymphoma ]]
|Disease
|Disease
|
|
Line 700: Line 768:
|
|
|
|
|-|[[BRST5:Gynaecomastia|Gynaecomastia]]
|-
|[[BRST5:Gynaecomastia|Gynaecomastia]]
|Disease
|Disease
|
|
Line 710: Line 779:
|
|
|
|
|-|[[BRST5:Carcinoma_in_situ|Carcinoma in situ]]
|-
|[[BRST5:Carcinoma_in_situ|Carcinoma in situ]]
|Disease
|Disease
|
|
Line 720: Line 790:
|
|
|
|
|-|[[BRST5:Invasive_carcinoma|Invasive carcinoma]]
|-
|[[BRST5:Invasive_carcinoma|Invasive carcinoma]]
|Disease
|Disease
|
|
Line 730: Line 801:
|
|
|
|
|-|[[BRST5:Metastases_to_the_breast|Metastases to the breast]]
|-
|[[BRST5:Metastases_to_the_breast|Metastases to the breast]]
|Disease
|Disease
|
|
Line 740: Line 812:
|
|
|
|
|-|[[BRST5:BRCA1/2-associated_hereditary_breast_and_ovarian_cancer_syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]
|-
|[[BRST5:BRCA1/2-associated_hereditary_breast_and_ovarian_cancer_syndrome|BRCA1/2-associated hereditary breast and ovarian cancer syndrome]]
|Disease
|Disease
|
|
Line 750: Line 823:
|
|
|
|
|-|[[BRST5:Cowden_syndrome|Cowden syndrome]]
|-
|[[BRST5:Cowden_syndrome|Cowden syndrome]]
|Disease
|Disease
|
|
Line 760: Line 834:
|
|
|
|
|-|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]
|-
|[[BRST5:Ataxia-telangiectasia|Ataxia-telangiectasia]]
|Disease
|Disease
|
|
Line 770: Line 845:
|
|
|
|
|-|[[BRST5:Li-Fraumeni_syndrome,_TP53-associated|Li-Fraumeni syndrome, TP53-associated]]
|-
|[[BRST5:Li-Fraumeni_syndrome,_TP53-associated|Li-Fraumeni syndrome, TP53-associated]]
|Disease
|Disease
|
|
Line 780: Line 856:
|
|
|
|
|-|[[BRST5:Li-Fraumeni_syndrome,_CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]
|-
|[[BRST5:Li-Fraumeni_syndrome,_CHEK2-associated|Li-Fraumeni syndrome, CHEK2-associated]]
|Disease
|Disease
|
|
Line 790: Line 867:
|
|
|
|
|-|[[BRST5:CDH1-associated_breast_cancer|CDH1-associated breast cancer]]
|-
|[[BRST5:CDH1-associated_breast_cancer|CDH1-associated breast cancer]]
|Disease
|Disease
|
|
Line 800: Line 878:
|
|
|
|
|-|[[BRST5:PALB2-associated_cancers|PALB2-associated cancers]]
|-
|[[BRST5:PALB2-associated_cancers|PALB2-associated cancers]]
|Disease
|Disease
|
|
Line 810: Line 889:
|
|
|
|
|-|[[BRST5:Peutz-Jeghers_syndrome|Peutz-Jeghers syndrome]]
|-
|[[BRST5:Peutz-Jeghers_syndrome|Peutz-Jeghers syndrome]]
|Disease
|Disease
|
|
Line 820: Line 900:
|
|
|
|
|-|[[BRST5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|-
|[[BRST5:Neurofibromatosis_type_1|Neurofibromatosis type 1]]
|Disease
|Disease
|
|